Home ›
NPI 1659581932
NPI deactivated
1659581932
1659581932 was paid $3.62M by Medicaid between Jan 2018 and Aug 2021, across 443 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 11% of everything it billed.
33Billing provider info1659581932
33aNPI1659581932
33bProvider type—
28Total paid$3.62M
24GClaims543,750
24DCodes billed443
24AFirst – last monthJan 2018 – Aug 2021
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 321,458 | $2.15M | |
| 2019 | 12,694 | $193K | |
| 2020 | 96,127 | $720K | |
| 2021 | 113,471 | $553K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 11% | 50,863 | 46,576 | $406K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.6% | 4,703 | 4,305 | $311K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 8.6% | 7,305 | 6,950 | $311K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 7.6% | 7,724 | 7,325 | $276K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 7.5% | 9,953 | 9,449 | $272K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 3.5% | 8,443 | 8,314 | $126K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 2.8% | 1,704 | 1,693 | $101K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.5% | 3,992 | 2,671 | $92K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 2.1% | 810 | 762 | $75K |
| 80053 | Comprehensive metabolic panel | 1.9% | 23,465 | 22,289 | $70K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 1.8% | 1,830 | 1,817 | $65K |
| 99223 | Prolong inpt eval add15 m | 1.6% | 423 | 396 | $56K |
431 more codes
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.4% | 7,111 | $50K |
| 86003 | 1.3% | 1,330 | $47K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.3% | 2,089 | $47K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1.3% | 902 | $46K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.2% | 538 | $43K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1.1% | 855 | $39K |
| E1390 | Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate | <1% | 323 | $34K |
| 59425 | <1% | 1,277 | $34K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,041 | $33K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 1,095 | $32K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 5,752 | $32K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 886 | $30K |
| J3490 | Unclassified drugs | <1% | 587 | $28K |
| A0427 | Emergency ambulance ride, advanced life support | <1% | 252 | $27K |
| 97001 | <1% | 379 | $27K | |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 599 | $27K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 498 | $26K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,128 | $26K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 511 | $26K |
| 99199 | Unlisted special service, procedure or report | <1% | 2,333 | $25K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 107 | $23K |
| 71045 | Radiologic examination, chest; single view | <1% | 4,504 | $22K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 8,906 | $20K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,275 | $19K |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 484 | $18K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 419 | $17K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 428 | $17K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 1,996 | $16K |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 82 | $16K |
| 3074F | <1% | 7,952 | $14K | |
| T4541 | Incontinence product, disposable underpad, large, each | <1% | 392 | $14K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,789 | $14K |
| 3008F | <1% | 16,025 | $14K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 1,791 | $14K |
| A0425 | Ground mileage, per statute mile | <1% | 726 | $14K |
| 90686 | <1% | 1,611 | $13K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 337 | $13K |
| 82785 | <1% | 746 | $13K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 3,477 | $12K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,034 | $12K |
| V2020 | Frames, purchases | <1% | 552 | $11K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,472 | $11K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 266 | $10K |
| 92340 | Fitting of spectacles, except for aphakia; monofocal | <1% | 523 | $10K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 687 | $10K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 298 | $10K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 28,631 | $10K |
| A0429 | Emergency ambulance ride, basic life support | <1% | 85 | $9K |
| 3078F | <1% | 6,601 | $9K | |
| 76830 | Ultrasound, transvaginal | <1% | 745 | $8K |
| 99205 | Prolong outpt/office vis | <1% | 74 | $8K |
| 99201 | <1% | 103 | $8K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 414 | $8K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 905 | $7K |
| 81001 | <1% | 16,414 | $7K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 2,249 | $7K |
| 95144 | <1% | 165 | $7K | |
| 95165 | Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials | <1% | 391 | $7K |
| 80055 | <1% | 482 | $7K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 750 | $6K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 224 | $6K |
| 92015 | Determination of refractive state | <1% | 784 | $6K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 28 | $6K |
| E0431 | Portable gaseous oxygen system, rental; includes portable container, regulator, flowmeter, humidifier, cannula or mask, and tubing | <1% | 264 | $6K |
| 97032 | <1% | 981 | $6K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 99 | $5K |
| 90649 | <1% | 707 | $5K | |
| 95117 | <1% | 388 | $5K | |
| S0199 | Medically induced abortion by oral ingestion of medication including all associated services and supplies (e.g., patient counseling, office visits, confirmation of pregnancy by hcg, ultrasound to confirm duration of pregnancy, ultrasound to confirm completion of abortion) except drugs | <1% | 13 | $5K |
| T4535 | Disposable liner/shield/guard/pad/undergarment, for incontinence, each | <1% | 126 | $5K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,012 | $5K |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 277 | $5K |
| 81025 | <1% | 1,786 | $5K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 311 | $5K |
| 90734 | <1% | 531 | $4K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 168 | $4K |
| 90658 | <1% | 506 | $4K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 142 | $4K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 70 | $4K |
| 99401 | <1% | 1,307 | $4K | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 56 | $4K |
| 00731 | <1% | 15 | $4K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 47 | $4K |
| 80061 | Lipid panel | <1% | 17,852 | $3K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 239 | $3K |
| 86580 | <1% | 808 | $3K | |
| 01967 | Neuraxial labor analgesia/anesthesia for planned vaginal delivery | <1% | 12 | $3K |
| 77066 | Tomosynthesis, mammo | <1% | 38 | $3K |
| 73630 | <1% | 761 | $3K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,282 | $3K |
| 85018 | <1% | 5,950 | $3K | |
| 73610 | <1% | 607 | $3K | |
| 86592 | <1% | 5,188 | $3K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 474 | $3K |
| 80074 | <1% | 2,542 | $3K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,533 | $3K |
| 97802 | <1% | 1,012 | $3K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 88 | $3K |
| 52281 | <1% | 12 | $3K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 230 | $2K |
| 90621 | <1% | 192 | $2K | |
| 90651 | <1% | 351 | $2K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 178 | $2K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 247 | $2K |
| 92250 | <1% | 57 | $2K | |
| 88304 | <1% | 85 | $2K | |
| H1001 | Prenatal care, at-risk enhanced service; antepartum management | <1% | 38 | $2K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 170 | $2K |
| L3670 | Shoulder orthosis, acromio/clavicular (canvas and webbing type), prefabricated, off-the-shelf | <1% | 28 | $2K |
| 73130 | <1% | 411 | $2K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 29 | $2K |
| 76641 | <1% | 127 | $2K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 272 | $2K |
| 87070 | <1% | 2,129 | $2K | |
| 76770 | <1% | 178 | $2K | |
| 90715 | <1% | 202 | $2K | |
| 83690 | <1% | 1,828 | $2K | |
| S9088 | Services provided in an urgent care center (list in addition to code for service) | <1% | 1,276 | $2K |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 962 | $2K |
| A4267 | Contraceptive supply, condom, male, each | <1% | 543 | $2K |
| 73030 | <1% | 384 | $2K | |
| 73562 | <1% | 588 | $2K | |
| 87480 | <1% | 113 | $2K | |
| 97163 | <1% | 12 | $2K | |
| 84484 | <1% | 996 | $2K | |
| 99460 | <1% | 33 | $2K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 15,461 | $2K |
| 80076 | <1% | 2,295 | $2K | |
| 92551 | <1% | 5,659 | $2K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 7,349 | $2K |
| 85027 | <1% | 2,875 | $2K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 106 | $2K |
| 87522 | Neg quan hep c or qual rna | <1% | 58 | $2K |
| 84702 | <1% | 1,397 | $1K | |
| 97014 | <1% | 271 | $1K | |
| 93970 | <1% | 32 | $1K | |
| 73110 | <1% | 296 | $1K | |
| 74018 | <1% | 336 | $1K | |
| 81003 | <1% | 3,892 | $1K | |
| 85610 | <1% | 2,845 | $1K | |
| 93976 | <1% | 170 | $1K | |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | <1% | 137 | $1K |
| 76642 | <1% | 279 | $1K | |
| 93325 | <1% | 98 | $1K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 93 | $1K |
| 72100 | <1% | 449 | $1K | |
| 00811 | <1% | 16 | $1K | |
| 81002 | <1% | 3,205 | $1K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 276 | $1K |
| 92226 | <1% | 13 | $1K | |
| 76870 | <1% | 46 | $989.00 | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 687 | $975.66 |
| 83880 | <1% | 299 | $970.96 | |
| 97010 | <1% | 948 | $936.40 | |
| 73090 | <1% | 140 | $896.04 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 6,326 | $895.46 |
| 93971 | <1% | 91 | $895.06 | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 83 | $876.05 |
| 73140 | <1% | 175 | $871.13 | |
| 86803 | <1% | 916 | $791.05 | |
| 85730 | <1% | 2,201 | $779.74 | |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 188 | $765.11 |
| 84703 | <1% | 790 | $758.29 | |
| 73221 | <1% | 15 | $750.00 | |
| 93000 | <1% | 216 | $748.96 | |
| 71250 | <1% | 13 | $745.05 | |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 28 | $687.03 |
| A6402 | Gauze, non-impregnated, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | <1% | 13 | $667.28 |
| 74022 | <1% | 56 | $644.92 | |
| A4927 | Gloves, non-sterile, per 100 | <1% | 1,374 | $642.84 |
| 73080 | <1% | 132 | $618.24 | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 57 | $618.19 |
| 99000 | <1% | 1,252 | $611.24 | |
| 90670 | <1% | 205 | $585.00 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 215 | $580.55 |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 811 | $567.90 |
| 77065 | Tomosynthesis, mammo | <1% | 14 | $560.00 |
| 73590 | <1% | 121 | $549.85 | |
| 73564 | <1% | 88 | $539.84 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 15,280 | $533.23 |
| 83735 | <1% | 984 | $528.62 | |
| 82962 | <1% | 1,171 | $510.50 | |
| E0570 | Nebulizer, with compressor | <1% | 12 | $500.00 |
| G0270 | Medical nutrition therapy; reassessment and subsequent intervention(s) following second referral in same year for change in diagnosis, medical condition or treatment regimen (including additional hours needed for renal disease), individual, face to face with the patient, each 15 minutes | <1% | 766 | $490.00 |
| 94760 | <1% | 479 | $486.38 | |
| 72110 | <1% | 66 | $456.20 | |
| 86769 | <1% | 16 | $442.35 | |
| 90656 | <1% | 123 | $442.06 | |
| 99406 | <1% | 186 | $426.81 | |
| 92002 | <1% | 92 | $425.74 | |
| 92552 | <1% | 3,336 | $401.09 | |
| 90716 | <1% | 190 | $399.48 | |
| 12011 | <1% | 22 | $394.97 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 108 | $387.03 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 153 | $386.66 |
| 83655 | <1% | 2,295 | $371.48 | |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 300 | $369.00 |
| A6250 | Skin sealants, protectants, moisturizers, ointments, any type, any size | <1% | 64 | $368.53 |
| 92557 | <1% | 26 | $366.18 | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 18 | $351.30 |
| 90633 | <1% | 141 | $351.00 | |
| 73502 | <1% | 88 | $350.24 | |
| 90707 | <1% | 151 | $348.24 | |
| 85007 | <1% | 714 | $346.57 | |
| 87806 | <1% | 6,456 | $339.31 | |
| 90698 | <1% | 73 | $333.00 | |
| 82947 | <1% | 633 | $325.97 | |
| 82043 | <1% | 3,459 | $312.19 | |
| 70486 | <1% | 14 | $300.59 | |
| 87186 | <1% | 2,084 | $298.15 | |
| 72040 | <1% | 116 | $288.20 | |
| 99173 | <1% | 5,745 | $287.29 | |
| 97035 | <1% | 219 | $282.41 | |
| 87040 | <1% | 193 | $275.14 | |
| 82950 | <1% | 568 | $275.11 | |
| 3079F | <1% | 1,289 | $275.00 | |
| 82607 | <1% | 2,628 | $269.59 | |
| 83605 | <1% | 97 | $252.66 | |
| 86901 | <1% | 499 | $237.75 | |
| 87081 | <1% | 624 | $234.86 | |
| 70360 | <1% | 14 | $231.96 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 250 | $224.12 |
| 86850 | <1% | 151 | $221.19 | |
| 3077F | <1% | 372 | $220.00 | |
| 82465 | <1% | 339 | $215.21 | |
| 99497 | <1% | 12 | $213.21 | |
| 85014 | <1% | 972 | $212.25 | |
| 87077 | <1% | 111 | $204.95 | |
| 84436 | <1% | 4,592 | $203.70 | |
| A4335 | Incontinence supply; miscellaneous | <1% | 119 | $191.52 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 34 | $190.73 |
| 82105 | <1% | 38 | $188.90 | |
| 86900 | <1% | 356 | $184.80 | |
| 83001 | <1% | 853 | $180.63 | |
| 99383 | <1% | 14 | $179.00 | |
| 82728 | <1% | 1,411 | $178.09 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,226 | $171.00 |
| 72050 | <1% | 13 | $168.52 | |
| 3075F | <1% | 284 | $165.00 | |
| 90713 | <1% | 88 | $160.16 | |
| 82150 | <1% | 346 | $158.81 | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 923 | $153.00 |
| 83970 | <1% | 83 | $137.96 | |
| 90700 | <1% | 166 | $134.08 | |
| 76536 | <1% | 57 | $130.72 | |
| 87210 | <1% | 610 | $128.78 | |
| 90744 | <1% | 26 | $126.00 | |
| 3044F | <1% | 68 | $120.00 | |
| 90680 | <1% | 26 | $117.00 | |
| 51798 | <1% | 41 | $116.40 | |
| 83540 | <1% | 1,647 | $114.36 | |
| 87088 | <1% | 733 | $111.93 | |
| 90688 | <1% | 12 | $108.00 | |
| 90685 | <1% | 12 | $108.00 | |
| 84100 | <1% | 414 | $107.17 | |
| 3080F | <1% | 176 | $100.00 | |
| 86317 | <1% | 231 | $99.81 | |
| 0450 | Emergency room services | <1% | 35 | $99.20 |
| 84439 | <1% | 3,823 | $95.40 | |
| 82746 | <1% | 1,577 | $91.27 | |
| 96156 | <1% | 394 | $83.46 | |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | <1% | 997 | $80.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 58 | $74.21 |
| 11901 | <1% | 12 | $73.48 | |
| 87400 | <1% | 86 | $71.48 | |
| 76942 | <1% | 14 | $71.43 | |
| 84153 | <1% | 1,421 | $70.88 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 216 | $70.00 |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 14 | $68.97 |
| 73060 | <1% | 16 | $68.69 | |
| 82247 | <1% | 68 | $67.27 | |
| 72070 | <1% | 27 | $64.71 | |
| 92133 | <1% | 31 | $64.50 | |
| 86140 | <1% | 1,518 | $59.50 | |
| 82550 | <1% | 233 | $57.18 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 42 | $54.67 |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 2,140 | $54.07 |
| 86695 | <1% | 957 | $48.64 | |
| 86141 | <1% | 432 | $48.29 | |
| 83550 | <1% | 1,457 | $40.39 | |
| 84403 | <1% | 655 | $39.59 | |
| 82040 | <1% | 198 | $37.74 | |
| 82248 | <1% | 1,298 | $37.39 | |
| 85379 | <1% | 41 | $36.38 | |
| 82270 | <1% | 1,348 | $36.28 | |
| 84481 | <1% | 1,490 | $32.84 | |
| 88312 | <1% | 29 | $32.50 | |
| 85652 | <1% | 2,778 | $29.60 | |
| G9920 | Screening performed and negative | <1% | 3,259 | $28.71 |
| 84550 | <1% | 2,522 | $28.31 | |
| 82951 | <1% | 61 | $25.01 | |
| 92081 | <1% | 1,156 | $24.02 | |
| 86038 | <1% | 1,543 | $21.26 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 98 | $20.84 |
| S9470 | Nutritional counseling, dietitian visit | <1% | 154 | $20.00 |
| 87340 | <1% | 387 | $19.87 | |
| 88142 | <1% | 214 | $18.13 | |
| 90620 | <1% | 18 | $18.00 | |
| 86696 | <1% | 994 | $17.20 | |
| 86301 | <1% | 94 | $16.52 | |
| 83026 | <1% | 246 | $16.16 | |
| 87510 | <1% | 113 | $14.30 | |
| 87660 | <1% | 113 | $14.22 | |
| 83615 | <1% | 207 | $14.06 | |
| 84460 | <1% | 206 | $13.59 | |
| 84479 | <1% | 3,315 | $13.51 | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | <1% | 814 | $10.70 |
| 97803 | <1% | 358 | $10.00 | |
| 85045 | <1% | 97 | $8.24 | |
| 81000 | <1% | 682 | $8.08 | |
| 87205 | <1% | 18 | $7.78 | |
| 86200 | <1% | 491 | $7.10 | |
| 82570 | <1% | 2,434 | $5.58 | |
| 86431 | <1% | 1,549 | $5.02 | |
| 86706 | <1% | 262 | $1.88 | |
| 84480 | <1% | 557 | $0.33 | |
| 82378 | 0% | 297 | $0.00 | |
| 83986 | 0% | 233 | $0.00 | |
| 1126F | 0% | 2,655 | $0.00 | |
| 83014 | 0% | 13 | $0.00 | |
| 1036F | 0% | 3,341 | $0.00 | |
| 1125F | 0% | 1,706 | $0.00 | |
| 1170F | 0% | 223 | $0.00 | |
| 1035F | 0% | 143 | $0.00 | |
| 83002 | 0% | 640 | $0.00 | |
| 88150 | 0% | 27 | $0.00 | |
| 82044 | 0% | 121 | $0.00 | |
| 84270 | 0% | 187 | $0.00 | |
| A4556 | Electrodes, (e.g., apnea monitor), per pair | 0% | 26 | $0.00 |
| 86704 | 0% | 512 | $0.00 | |
| 80050 | General health panel | 0% | 97 | $0.00 |
| 92060 | 0% | 419 | $0.00 | |
| 86160 | 0% | 147 | $0.00 | |
| 96127 | 0% | 414 | $0.00 | |
| 86376 | 0% | 357 | $0.00 | |
| 0545F | 0% | 15 | $0.00 | |
| 84154 | 0% | 158 | $0.00 | |
| 88141 | 0% | 172 | $0.00 | |
| 99441 | 0% | 46 | $0.00 | |
| 82670 | 0% | 282 | $0.00 | |
| 83021 | 0% | 43 | $0.00 | |
| 86255 | 0% | 41 | $0.00 | |
| 36416 | 0% | 188 | $0.00 | |
| 82120 | 0% | 225 | $0.00 | |
| G0442 | Annual alcohol misuse screening, 5 to 15 minutes | 0% | 68 | $0.00 |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source | 0% | 48 | $0.00 |
| 3014F | 0% | 26 | $0.00 | |
| 2010F | 0% | 28 | $0.00 | |
| 87511 | 0% | 19 | $0.00 | |
| S0302 | Completed early periodic screening diagnosis and treatment (epsdt) service (list in addition to code for appropriate evaluation and management service) | 0% | 13 | $0.00 |
| 1111F | 0% | 132 | $0.00 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 0% | 18 | $0.00 |
| G8420 | Bmi is documented within normal parameters and no follow-up plan is required | 0% | 136 | $0.00 |
| 82952 | 0% | 13 | $0.00 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 85 | $0.00 |
| 86225 | 0% | 145 | $0.00 | |
| A9270 | Non-covered item or service | 0% | 18 | $0.00 |
| 96151 | 0% | 43 | $0.00 | |
| 86762 | 0% | 25 | $0.00 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 0% | 13 | $0.00 |
| 96150 | 0% | 16 | $0.00 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 0% | 16 | $0.00 |
| 87430 | 0% | 52 | $0.00 | |
| 82784 | 0% | 26 | $0.00 | |
| 2001F | 0% | 65 | $0.00 | |
| 0001F | 0% | 62 | $0.00 | |
| 86710 | 0% | 17 | $0.00 | |
| 3352F | 0% | 15 | $0.00 | |
| 86304 | 0% | 40 | $0.00 | |
| 2000F | 0% | 20 | $0.00 | |
| 1034F | 0% | 13 | $0.00 | |
| 1159F | 0% | 2,926 | $0.00 | |
| G8431 | Screening for depression is documented as being positive and a follow-up plan is documented | 0% | 15 | $0.00 |
| 1160F | 0% | 2,629 | $0.00 | |
| 86708 | 0% | 447 | $0.00 | |
| 3725F | 0% | 1,885 | $0.00 | |
| 84146 | 0% | 478 | $0.00 | |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | 0% | 15 | $0.00 |
| 82652 | 0% | 404 | $0.00 | |
| 83516 | 0% | 96 | $0.00 | |
| 86677 | 0% | 526 | $0.00 | |
| 0502F | 0% | 107 | $0.00 | |
| 87045 | 0% | 43 | $0.00 | |
| 99072 | 0% | 45 | $0.00 | |
| 87338 | 0% | 396 | $0.00 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 12 | $0.00 |
| 84450 | 0% | 116 | $0.00 | |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | 0% | 31 | $0.00 |
| 83013 | 0% | 13 | $0.00 | |
| 99442 | 0% | 423 | $0.00 | |
| 87209 | 0% | 141 | $0.00 | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | 0% | 95 | $0.00 |
| 3288F | 0% | 76 | $0.00 | |
| 4005F | 0% | 15 | $0.00 | |
| 96160 | 0% | 255 | $0.00 | |
| 86235 | 0% | 71 | $0.00 | |
| 90461 | 0% | 127 | $0.00 | |
| 82977 | 0% | 13 | $0.00 | |
| 83721 | 0% | 270 | $0.00 | |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 200 | $0.00 |
| 86480 | 0% | 369 | $0.00 | |
| 1003F | 0% | 29 | $0.00 | |
| 97012 | 0% | 186 | $0.00 | |
| 83525 | 0% | 61 | $0.00 | |
| 99188 | 0% | 37 | $0.00 | |
| G0444 | Annual depression screening, 5 to 15 minutes | 0% | 75 | $0.00 |
| 4004F | 0% | 28 | $0.00 | |
| 84156 | 0% | 47 | $0.00 | |
| 87177 | 0% | 141 | $0.00 | |
| 73100 | 0% | 16 | $0.00 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 0% | 49 | $0.00 |
| 90472 | Immunization administration, each additional vaccine (list separately) | 0% | 51 | $0.00 |
| 92550 | 0% | 12 | $0.00 | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | 0% | 52 | $0.00 |
| 80305 | 0% | 79 | $0.00 | |
| 11721 | 0% | 120 | $0.00 | |
| H1003 | Prenatal care, at-risk enhanced service; education | 0% | 59 | $0.00 |
| 0521F | 0% | 15 | $0.00 | |
| 3015F | 0% | 34 | $0.00 | |
| 87481 | 0% | 19 | $0.00 | |
| 99242 | 0% | 58 | $0.00 | |
| 92020 | 0% | 27 | $0.00 | |
| 82274 | 0% | 12 | $0.00 | |
| 92588 | 0% | 13 | $0.00 | |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | 0% | 13 | $0.00 |
| 90648 | 0% | 13 | $0.00 | |
| 84681 | 0% | 13 | $0.00 | |
| 82565 | 0% | 32 | $0.00 | |
| 97161 | 0% | 14 | $0.00 | |
| 92083 | 0% | 31 | $0.00 | |
| 99053 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.